Patients with mutant AML are routinely treated in the upfront setting with chemotherapy plus midostaurin, a multitargeted tyrosine kinase with FLT3 inhibitory activity 6 min read Annexin Patients with mutant AML are routinely treated in the upfront setting with chemotherapy plus midostaurin, a multitargeted tyrosine kinase with FLT3 inhibitory activity cmerp January 26, 2023 Patients with mutant AML are routinely treated in the upfront setting with chemotherapy plus midostaurin, a multitargeted...Read More